LCN2 and breast cancer: Finally, core biopsies of 652 breast cancer patients undergoing neoadjuvant chemotherapy, examined via immunohistochemistry, revealed that the intensity and expression of Lcn-2 were significantly related to estrogen and progesterone receptor status, as well as with the histological tumor type [103].